A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Active, not recruiting · NCT05159700 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, central nervous system malformation, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Active, not recruiting | Phase 1 | 2025-12-15 | NCT05159700 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhuhai Yufan Biotechnologies Co., Ltd | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Christ Hospital | Cincinnati | United States | 1 |
| Mays Cancer Center | San Antonio | United States | 12 |
| NEXT Oncology | Fairfax | United States | 31 |
| NEXT Oncology | Austin | United States | 1 |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | United States | 11 |
| Sarah Cannon Research Institute at HealthOne | Denver | United States | 34 |